The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery

Molecular Biology Reports

Volumn 38, Issue 5, 2011, Pages 3383-3389

  Yaǧar, Seyhan ^a   Yavaş, Soner ^a   Karahalil, Bensu ^b  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

Alpha 2a; Dexmedetomidine; Genetic polymorphism.

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; DEXMEDETOMIDINE; FENTANYL; MIDAZOLAM; ROCURONIUM;

ADULT; AGED; ANESTHESIOLOGICAL TECHNIQUES; ARTICLE; BISPECTRAL INDEX; CORONARY ARTERY SURGERY; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENOTYPE; HAPLOTYPE; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEDATION; SLEEP; SURGICAL PATIENT;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; CORONARY ARTERY BYPASS; CORONARY VESSELS; DEXMEDETOMIDINE; FEMALE; GENOTYPE; HEMODYNAMICS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 80052483095     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0446-y     Document Type: Article

References (32)

1. Kalow W, Tang BK, Endrenyi L (1998) Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug eesearch. Pharmacogenetics 8(4):283-289 (Pubitemid 28372321)
2. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671
3. Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7:201-204 (Pubitemid 32822891)
4. McCharty AD, Kennedy JL, Middleton TL (2005) Pharmacogenetics in drug development. Philos Trans R Soc B 360:1579-1588
5. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R (1997) Association between genetic polymorphisms of the beta2- adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100:3184-3188 (Pubitemid 28022857)
6. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW, Price J, Collier DA, Kerwin RW (1995) Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7:169-172 (Pubitemid 26077220)
7. Ebstein RP, Novick O, Umansky R et al (1996) Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 12:81-84
8. Arinami T, Gao M, Hamaguchi H et al (1997) A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6:577-582 (Pubitemid 27142107)
9. Insel PA (1996) Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors-evolving concepts and clinical implications. New Engl J Med 334:580-585
10. Bhana N, Goa KL, McClellan KJ (2000) Dexmedetomidine. Drugs 2000; 59: 263-268. (Pubitemid 30168513)
11. Bradley C. Dexmedetomidine-a novel sedative for postoperative sedation. Intensive Crit Care Nurs 16:328-329
12. Belfer I, Buzas B, Hipp H, Philips G, Taunman J, Loricz I et al (2005) Haplotyped-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene. J Hum Genet 50:12-20 (Pubitemid 40248310)
13. Pfost DR, Boyce-Jacino MT, Grant DM (2000) A SNPshot: pharmacogenetics and the future of drug therapy. Trends Biotechnol 18:334-338 (Pubitemid 30456347)
14. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD (2008) Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 8:1009-1015
15. Jose L, Binila C, Chandy SJ, Mathews JE, Mathews KP (2008) Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation. J Assoc Phys India 6:250-252
16. Malhi H, Atac B, Daly AK, Gupta S (2004) Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad Med J 80:107-109 (Pubitemid 38297245)
17. Kocabaş NA, Karahalil B (2006) XRCC1 Arg399Gln genetic polymorphism in a Turkish population. Int J Toxicol 25:419-422 (Pubitemid 44385167)
18. Tsai SJ, Wang YC, Hong CJ (2001) Allelic variants of the a1A adrenoceptor and the promoter region of the a2Aadrenoceptor and temperament factors. Am J Med Genet 105:96-98
19. Roman T, Schimitz M, Polanczyk GV, Eizirik M, Rohde LA, Hutz MH (2003) Is the a2A-adrenergic receptor gene (ADRA2A) associated with attention-deficit/ hyperactivity disorder? Neuropsychol Genet 120B:116-120 (Pubitemid 37059387)
20. Schmitz M, Denardin D, Silva TL, Pianca T, Roman T, Hutz MH, Faraone SV, Rohde LA (2006) Association between alpha-2aadrenergic receptor gene and ADHD inattentive type. Biol Psychiatry 60:1028-1033 (Pubitemid 44647211)
21. Park L, Nigg JT, Waldman ID, Nummy KA, Huang-Pollock C, Rappley M, Friderici KH (2005) Association and linkage of α-2A adrenergic receptor gene polymorphisms with childhood ADHA. Mol Psychiatry 10:572-580 (Pubitemid 40897041)
22. Karahalil B, Coskun E, Emerce E (2008) ADRA2A polymorphism and smoking in a Turkish population. Toxicol Ind Health 24:171-176
23. Hunter JC, Fontana DJ, Hedley LR, Jasper JR, Lewis R, Link RE et al (1997) Assessment of the role of alpha2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 122:1339-1344 (Pubitemid 27503923)
24. 2A-adrenergic receptor mice unveil unique therapeutic benefits of partial agonists. PNAS 99:12471-12476
25. Kurnik D, Muszkat M, Sofowora GG, Friedman EA, Dupont WD, Scheinin M et al (2008) Ethnic and genetic determinants of cardiovascular response to the selective α2A-adrenoceptor agonist dexmedetomidine. Hypertension 51:406-411 (Pubitemid 351159957)
26. Kohli U, Muszkat M, Sofowora GG, Harris PA, Friedman EA, Dupont WD, Scheinin M, Wood AJJ, Stein CM, Kurnik D (2009) effects of variation in the human α2A- and α2C-adrenoceptor genes on cognitive tasks and pain perception. Eur J Pain. doi: 10.1016/j.ejpain.2009.04.003
27. Polanczyk G, Zeni C, Genro JP, Guimaraes GP, Roman T, Hutz MH, Rohde LA (2007) Association of the adrenergic α2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychatry 64:218-224 (Pubitemid 46220779)
28. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC et al (2006) Weight gain associated with the α2A-adrenergic receptor- 1291C/G polymorphism and olanzapine treatment. Am J Med Genet B 141:394-397 (Pubitemid 43872892)
29. Lee HY, Kang RH, Paik JW, Jeong JY, Chang HS, Han SW, Lee MS (2009) Association of the adrenergic alpha 2a receptor- 1291C/G polymorphism with wight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Res 25:1-6
30. McCracken JT, Aman MG, McDougle CJ, Tierney E, Shiraga S, Whelan F, Arnold LE, Posey D, Ritz L, Vitiello B, Scahill L (2010) Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J Child Adolesc Psychopharmacol 20:1-5
31. Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, MÜller MJ (2010) Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 140:278-284
32. Stocco G, Crews KR, Evans WE (2010) Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyltransferase status. Expert Opin Drug Saf 9:23-37